PCSK9 and chronic kidney disease: In this study, based on the large-scale study population in UK Biobank, we conducted 2×2 factorial MR analyses to evaluate the interactions between different lipid-lowering drugs (statins and PCSK9 inhibitors) and antihypertensive drugs (BBs and calcium channel blockers [CCBs]) on risk of CVD (defined as a composite of CAD, stroke and peripheral artery diseases [PAD]), other clinical and safety outcomes (ischemic stroke [IS], hemorrhagic stroke [HS], heart failure [HF], DM, chronic kidney disease [CKD], and dementia).